



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known	
Application Number	10/536950
Filing Date	May 31, 2005
First Named Inventor	Thomas Herget
Art Unit	1725
Examiner Name	Not Yet Assigned
Attorney Docket Number	DFMP-P01-480

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-4,665,098	05-12-1987	Gibbs et al.	
	AB*	US-5,391,766	02-21-1995	Klaus et al.	
	AC*	US-5,428,071	06-27-1995	Bollag et al.	
	AD*	US-6,156,312	12-05-2000	Leskovar	
	AE*	US-6,197,809	03-06-2001	Strelchenok	
	AF*	US-6,274,747	08-14-2001	Strelchenok	
	AG*	US-6,326,397	12-04-2001	Bollag et al.	
	AH*	US-6,403,554-A1	11-01-2001	Strelchenok	
	AI*	US-6,506,796	01-14-2003	Fesus et al.	
	AJ*	US-6,593,359	07-15-2003	Fesus et al.	
	AK*	US-6,686,386	02-03-2004	Fesus et al.	
	AL*	US-2001-0018425-A1	08-30-2001	Strelchenok	
	AM*	US-2001-0018456-A1	08-30-2001	Fesus et al.	
	AN*	US-2001-0037032-A1	11-01-2001	Strelchenok	
	AO*	US-2002-0143062-A1	10-03-2002	Lopez-Berestein et al.	
	AP*	US-2003-0092758-A1	05-15-2003	Fesus et al.	
	AQ*	US-2003-0180719-A1	09-25-2003	Herget et al.	
	AR*	US-2004-0053832-A1	03-18-2004	Leskovar	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	BL	EP 0 552 624 B1	06-28-2000	F. HOFFMANN-LA ROCHE AG	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: These application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.809)(c)(ii)) because that application was filed after June 30, 2003 or is available in the F.W. *Applicant's unique citation designation number (optional). *See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶		
	CC	CHARPENTIER et al., Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes. J. Med. Chem. 38(26): 4993-5005, 1995.			
	CD	DAWSON et al., Correlation of retinoid binding affinity to retinoic acid receptor alpha with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells. Cancer Res. 55(19): 4446-51, 1995.			
	CE	EYROLLES et al., Retinobenzoic acids. 6. Retinoid antagonists with a heterocyclic ring. J. Med. Chem. 37(10): 1508-17, 1994.			
	CF	HAMAMOTO et al., 9-cis retinoic acid enhances the antiviral effect of interferon on hepatitis C virus replication through increased expression of type I interferon receptor. J. Lab. Clin. Med. 141(1): 58-66, 2003.			
Examiner Signature				Date Considered	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TPT/



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/536950
		Filing Date	May 31, 2005
		First Named Inventor	Thomas Herget
		Art Unit	1725
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	DFMP-P01-480
Sheet	2	of	2

CG	KAGENCHIKA et al., Inhibition of IL-1-Induced IL-6 Production by Synthetic Retinoids. Biochemical and Biophysical Research Communications 231: 243-248, 1997.	
CH	KANEKO et al., Med. Chem. Res. 1: 220-225, 1991.	
CI	KOCH et al., Identification of the first retinoid X ₂ receptor homodimer antagonist. J. Med. Chem. 39(17): 3229-34, 1996.	
CJ	LALA et al., Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature 383: 450 - 453, 1996.	
CK	LEE et al., A novel class of retinoid antagonists and their mechanism of action. J. Biol. Chem. 271(20): 11897-903, 1996.	
CL	LOHMANN et al., Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285(5424): 110-3, 1999.	
CM	TENG et al., Identification of highly potent retinoic acid receptor alpha-selective antagonists. J. Med. Chem. 40(16): 2445-51, 1997.	
CN	YOSHIMURA et al., A novel type of retinoic acid receptor antagonist: synthesis and structure-activity relationships of heterocyclic ring-containing benzoic acid derivatives. J. Med. Chem. 38(16): 3163-73, 1995.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Timothy Thomas/	Date Considered	04/29/2008
-----------------------	------------------	--------------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TPT/